mathom/ct_dataset huggingface dataset:
Provide description for trial id: NCT01064349  
 This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression.
Trial Id: RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients Recruitment Status: Unknown status Trail description: This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy. Inclusion Criteria: Invasive carcinoma of the breast.
Complete microscopic excision of primary tumour and axillary dissection or SLNB .
Females with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy.
Patients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront mastectomy.
Able to comply with follow up.
Written informed consent Exclusion Criteria: Patients do not match with inclusion criteria.
Collagen vascular disease, specifically systemic lupus, or scleroderma.
Pregnancy or lactation at the time of radiotherapy.
Provide inclusion criteria for trial id: NCT04550910  
 Invasive carcinoma of the breast.
Complete microscopic excision of primary tumour and axillary dissection or SLNB .
Females with locally advanced breast cancer ( T3/T4 or N + or both ) who are candidate for neoadjvant chemotherapy regardless pathological stage after mastectomy.
Patients with pathological stage (T3/ T4, +/- N+) or ( N+, any T) after upfront mastectomy.
Able to comply with follow up.
Written informed consent
Provide description for trial id: NCT04550910  
 This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy.
Trial Id: Persistent Organic Pollutants and Breast Cancers (POPCASE) Recruitment Status: Recruiting Trail description: Exposure to certain classes of chemical contaminants, including certain persistent organic pollutants (POPs) with a character of endocrine disruptors, could be one of the factors that lead to increase incidence of breast cancer in the Western world .

However, the causal role of POPs in the onset of breast cancer remains nowadays unproven. Preliminary epidemiological studies on the impact of these environmental factors in breast cancer etiology have ignored the critical periods of exposure. Similarly, they have considered a limited number of pollutants (not including possible joint or synergistic effects between individual compounds) and did not distinguish the different breast cancer subtypes may have different etiologies or even of genetic susceptibility factors (POP polymorphism of detoxification enzymes).

Thus, POPCASE study examines the association between the presence of breast cancer and the levels and exposure profiles to a group of POPs measured in adipose tissue (AT) and blood, in particular using spectrometric methods developed by the team LABERCA (Nantes, France). These internal levels of POPs (organochlorine pesticides, dioxins, PCBs, brominated flame retardants) will be measured both quantitatively (tissue concentrations) and qualitative (relative proportions of different pollutants sought). Inclusion Criteria: Women ≥ 18 and <75 years

According to the arm:

Arm A: histologically confirmed diagnosis of invasive breast cancer (only), unilateral or bilateral, outside off recurrence and relapse. Patients who have been supported for a contralateral breast cancer can be included if a period of at least 2-years between the last systemic treatment of inclusion in the study.
Arm B: Any woman operated on for breast plastic surgery (breast lift and breast reduction cure only)
Performance status (WHO) ≤ 1

5. Patient affiliated to a social security scheme, 6. Patient who signed and dated informed consent form 7. Arm A only: unifocal lesion 8. Arm A only: Clinical stage M0 Exclusion Criteria: Patient with uncontrolled infection
Patient pregnant or lactating
Patient with a viral infection (HIV, Hepatitis B, Hepatitis C)
Patient cannot be regularly monitored for psychological reasons, social, family or geographical.
Patient Private of liberty or under a guardianship authority / curatorship.
Arm A only: Patient to benefit from neoadjuvant therapy for breast cancer
Arm A only Patient with metastatic breast cancer
Arm A only Patient diagnosed cancer in situ (intra ductal)
Arm A only Patient with BRCA1 or BRCA2 known
Arm B only: previous breast plastic surgery, regardless of the type of intervention
Provide inclusion criteria for trial id: NCT02890095  
 Women ≥ 18 and <75 years

According to the arm:

Arm A: histologically confirmed diagnosis of invasive breast cancer (only), unilateral or bilateral, outside off recurrence and relapse. Patients who have been supported for a contralateral breast cancer can be included if a period of at least 2-years between the last systemic treatment of inclusion in the study.
Arm B: Any woman operated on for breast plastic surgery (breast lift and breast reduction cure only)
Performance status (WHO) ≤ 1

5. Patient affiliated to a social security scheme, 6. Patient who signed and dated informed consent form 7. Arm A only: unifocal lesion 8. Arm A only: Clinical stage M0
Provide exclusion criteria for trial id: NCT02890095  
 Patient with uncontrolled infection
Patient pregnant or lactating
Patient with a viral infection (HIV, Hepatitis B, Hepatitis C)
Patient cannot be regularly monitored for psychological reasons, social, family or geographical.
Patient Private of liberty or under a guardianship authority / curatorship.
Arm A only: Patient to benefit from neoadjuvant therapy for breast cancer
Arm A only Patient with metastatic breast cancer
Arm A only Patient diagnosed cancer in situ (intra ductal)
Arm A only Patient with BRCA1 or BRCA2 known
Arm B only: previous breast plastic surgery, regardless of the type of intervention
Provide description for trial id: NCT02890095  
 Exposure to certain classes of chemical contaminants, including certain persistent organic pollutants (POPs) with a character of endocrine disruptors, could be one of the factors that lead to increase incidence of breast cancer in the Western world .

However, the causal role of POPs in the onset of breast cancer remains nowadays unproven. Preliminary epidemiological studies on the impact of these environmental factors in breast cancer etiology have ignored the critical periods of exposure. Similarly, they have considered a limited number of pollutants (not including possible joint or synergistic effects between individual compounds) and did not distinguish the different breast cancer subtypes may have different etiologies or even of genetic susceptibility factors (POP polymorphism of detoxification enzymes).

Thus, POPCASE study examines the association between the presence of breast cancer and the levels and exposure profiles to a group of POPs measured in adipose tissue (AT) and blood, in particular using spectrometric methods developed by the team LABERCA (Nantes, France). These internal levels of POPs (organochlorine pesticides, dioxins, PCBs, brominated flame retardants) will be measured both quantitatively (tissue concentrations) and qualitative (relative proportions of different pollutants sought).
Trial Id: Prospective Screening for Breast Cancer-related Lymphedema Recruitment Status: Recruiting Trail description: The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening. Inclusion Criteria: Confirmed diagnosis of breast cancer
Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid) Exclusion Criteria: Evidence of distant metastatic disease that may cause edema,
Previous breast cancer
History of lymphedema
Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS)
Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure).
Provide description for trial id: NCT01521741  
 The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening.
Trial Id: Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer. Recruitment Status: Unknown status Trail description: The purpose of the study is to estimate the diagnostic accuracy of preoperative ultrasound-guided axillary lymph node biopsy for staging in patients with newly diagnosed breast cancer, and also to compare between ultrasound-guided fine needle aspiration cytology and core needle biopsy in their ability to detect metastatic disease in the axillary lymph nodes of patients with breast cancer. Inclusion Criteria: Newly diagnosed patients with operable breast cancer regardless of whether lymph nodes are suspicious or not. Exclusion Criteria: Patients who had previously undergone axillary surgery.
Patients with metastatic disease and not planned for axillary surgery.
Patients with a preoperative diagnosis of a benign lesion or ductal carcinoma in situ.
Patients with severe uncorrectable bleeding diathesis.
Patients refused to sign consent.
Trial Id: Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers Recruitment Status: Terminated Trail description: This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers. The intra-tumoral and systemic immune response to cryoablation will be determined and compared to pre-ablated breast cancer specimens and historical control specimens. Inclusion Criteria: Subjects with an invasive breast cancer 1.5 cm or less
The breast cancer must be of ductal histology, unifocal, estrogen receptor positive and her2/neu negative.
The tumor must be visible by ultrasound and the subject must not have had prior surgical resection of the primary lesion.
A clip marking the breast cancer must have been placed at the time of initial diagnosis or will be placed prior to cryotherapy.
The breast cancer must be amenable to cryoablation (visible by ultrasound and more than 2 mm from skin or chest wall).
Subjects with metastatic disease at diagnosis who elect to have their primary tumor excised are eligible for enrollment.
For subjects with breast implants, the treating physician must document that adequate distance exists between the lesion and the implant to ensure that the ablated lesion with not contact or jeopardize the implant.
Subjects must be able to provide consent. Exclusion Criteria: Subjects with breast cancers of lobular histology, with lymph vascular invasion or extensive intraductal component will be excluded.
Subjects with multi-centric or multi-focal breast cancers
Subjects with breast cancers that have invaded skin or have significant skin tethering (assessed clinically).
Subjects receiving chemotherapy within one year or undergoing neoadjuvant chemotherapy are excluded.
Subjects with metastatic disease at diagnosis will be excluded unless they elect definitive surgical therapy for their primary lesion.
Subjects with breast cancers not amenable to cryoablation (lesions not visible by ultrasound, against the chest wall or within 2 mm of skin) will be excluded.
Subjects diagnosed with another malignancy in the preceding 5 years will be excluded.
Subjects diagnosed with simultaneous bilateral breast cancer.
Subjects receiving immunosuppressive therapy within 6 months including oral steroids will be excluded.
Provide inclusion criteria for trial id: NCT01856036  
 Subjects with an invasive breast cancer 1.5 cm or less
The breast cancer must be of ductal histology, unifocal, estrogen receptor positive and her2/neu negative.
The tumor must be visible by ultrasound and the subject must not have had prior surgical resection of the primary lesion.
A clip marking the breast cancer must have been placed at the time of initial diagnosis or will be placed prior to cryotherapy.
The breast cancer must be amenable to cryoablation (visible by ultrasound and more than 2 mm from skin or chest wall).
Subjects with metastatic disease at diagnosis who elect to have their primary tumor excised are eligible for enrollment.
For subjects with breast implants, the treating physician must document that adequate distance exists between the lesion and the implant to ensure that the ablated lesion with not contact or jeopardize the implant.
Subjects must be able to provide consent.
Provide exclusion criteria for trial id: NCT01856036  
 Subjects with breast cancers of lobular histology, with lymph vascular invasion or extensive intraductal component will be excluded.
Subjects with multi-centric or multi-focal breast cancers
Subjects with breast cancers that have invaded skin or have significant skin tethering (assessed clinically).
Subjects receiving chemotherapy within one year or undergoing neoadjuvant chemotherapy are excluded.
Subjects with metastatic disease at diagnosis will be excluded unless they elect definitive surgical therapy for their primary lesion.
Subjects with breast cancers not amenable to cryoablation (lesions not visible by ultrasound, against the chest wall or within 2 mm of skin) will be excluded.
Subjects diagnosed with another malignancy in the preceding 5 years will be excluded.
Subjects diagnosed with simultaneous bilateral breast cancer.
Subjects receiving immunosuppressive therapy within 6 months including oral steroids will be excluded.
Provide description for trial id: NCT01856036  
 This protocol will study the impact of cryoablation on immune response in patients diagnosed with invasive breast cancers smaller than 1.5 cm. It will profile the immune response to cryoablation of invasive breast cancers. The intra-tumoral and systemic immune response to cryoablation will be determined and compared to pre-ablated breast cancer specimens and historical control specimens.
Trial Id: Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients Recruitment Status: Completed Trail description: RATIONALE: Multi-faceted provider education and decision support intervention will increase the rate of appropriate referral of breast cancer patients at increased risk for hereditary breast and ovarian cancer (HBOC) to genetic counseling.

PURPOSE: This cluster randomized controlled trial will compare active and passive interventions to increase the rate of appropriate genetic counseling referrals of newly diagnosed breast cancer patients at increased risk for HBOC to genetic counseling in the community oncology setting. Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT01789684  
 RATIONALE: Multi-faceted provider education and decision support intervention will increase the rate of appropriate referral of breast cancer patients at increased risk for hereditary breast and ovarian cancer (HBOC) to genetic counseling.

PURPOSE: This cluster randomized controlled trial will compare active and passive interventions to increase the rate of appropriate genetic counseling referrals of newly diagnosed breast cancer patients at increased risk for HBOC to genetic counseling in the community oncology setting.
Trial Id: Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer Recruitment Status: Unknown status Trail description: This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features. Inclusion Criteria: Patients with invasive ductal carcinoma
Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon
Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response
Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines. Exclusion Criteria: Patients under 18 years old or during pregnancy
Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment
Provide inclusion criteria for trial id: NCT01597999  
 Patients with invasive ductal carcinoma
Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon
Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response
Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines.
Trial Id: The Effect of a Patient Decision Aids for Breast Cancer Screening Recruitment Status: Unknown status Trail description: Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres.

A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted. Inclusion Criteria: Women from 50 to 69 years old
Attend the primary care centres
Fluent in Spanish Exclusion Criteria: Women with a personal history of breast cancer
Have a current mammogram (as recommended by the Chilean Ministry of Health)
Not having the capacity to consent.
Provide description for trial id: NCT04948983  
 Breast cancer is one of the most common cancers in Chile. National efforts focus on early detection, offering universal access to breast cancer screening through mammography to women at risk age. However, 30% of women do not undertake the exam due to a lack of knowledge and anxiety when facing the decision. The aim of this study is to develop and evaluate the effectiveness of a decision aid (DA) for women facing breast cancer screening decision in the country. Methods: following the Medical Research Council guidelines for the development and implementation of a complex intervention in public health, the investigators have: 1) culturally adapted the German DA for mammography; 2) conducted focus groups with experts to further develop the DA; 3) pilot-tested the online DA with 20 women in primary care centres.

A total of 3,269 women aged 50 to 69 years old are invited to join the study. The intervention group accesses a webpage, answers a set of questionnaires at baseline, and then the DA (developed according to the IPDAS recommendations). The Control group accesses a webpage, answers a set of questionnaires at baseline, and then receives standardised information given by the healthcare system. Both groups complete the questionnaires two weeks later. The primary outcome measure is an adapted and validated version of Informed Choice. Additionally, decisional conflict, anxiety, and screening undertake rate are measured. Multiple lineal regression analysis will be conducted.
Trial Id: Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs Recruitment Status: Completed Trail description: The objective of this study is to determine the breast cancer risk of Mirena® users compared to copper intrauterine device (IUD) users in a community-based case-control study. Inclusion Criteria: cases: women with a breast cancer who are younger than 50 years of age at cancer diagnosis
controls: women without a breast cancer diagnosis who are younger than 50 years at the time of the interview Exclusion Criteria: women who are not willing to participate
Trial Id: Clinical Pilot Study for Personalized Risk-based Breast Cancer Screening Recruitment Status: Recruiting Trail description: The study aims to evaluate the impact of implementing population-based genetics testing strategy for breast cancer precision prevention using the polygenic risk score and monogenic pathogenic variant (MPV) testing in the Norwegian healthcare setting. Inclusion Criteria: Women referred for clinical mammography in the Vestre Viken Breast Centre
Breast density BI-RADS a or d
40-50 y.o. Exclusion Criteria: Prior history of breast cancer or premalignant breast disease
Prior genetic counselling/testing